Microparticles manufactured in an oil-in-water process comprising a prostamide
US-9101583-B2 · Aug 11, 2015 · US
Oil-in-water method for making polymeric implants containing a hypotensive lipid
US9707238B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9707238-B2 |
| Application number | US-201514822646-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 10, 2015 |
| Priority date | Apr 30, 2004 |
| Publication date | Jul 18, 2017 |
| Grant date | Jul 18, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.
First claim
Opening claim text (preview).
We claim: 1. A population of microparticles comprising a polymeric component encapsulating travoprost in the form of oil-in-water emulsified microparticles. 2. The population of claim 1 , wherein the polymeric component comprises a poly(lactide-co-glycolide) copolymer. 3. The population of claim 1 which is terminally sterilized. 4. The population of claim 3 , wherein at least 80% of the travoprost remains stable after the sterilization. 5. The population of claim 1 having a mean particle diameter from about 30 μm to about 50 μm. 6. The population of claim 1 , wherein the maximum particle diameter is less than about 200 μm. 7. The population of claim 1 , wherein the microparticles have a release rate of the travoprost of about 0.7% per day in vitro. 8. The population of claim 1 , wherein the travoprost comprises about 10% wt/wt of the microparticles. 9. The population of claim 1 , wherein the travoprost comprises about 5% wt/wt of the microparticles. 10. A method of treating an ocular condition in an eye of a patient, comprising the step of placing the population of claim 1 in an eye of a patient. 11. The method of claim 10 which is effective to treat glaucoma. 12. The method of claim 10 which is effective to decrease intraocular pressure.
Assignees
Inventors
Classifications
by phase separation · CPC title
by physical processes, e.g. drying, spraying · CPC title
Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)} · CPC title
Ocular inserts or implants · CPC title
having aromatic rings, e.g. colchicine, atenolol, progabide · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9707238B2 cover?
- Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, su…
- Who is the assignee on this patent?
- Allergan Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5575. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).